Our latest news on Magmaris RMS

RSS feed - (opens in new window) View all headlines -
20
September
2022
| 15:41 Europe/Amsterdam

BIOSOLVE-IV Full-Cohort Two-Year Data Confirm Excellent Safety and Efficacy Profile of Magmaris Resorbable Magnesium Scaffold

Magmaris Scaffold Performs Well in Real World Settings Even in More Complex Patient Groups

BIOTRONIK announced the presentation of new full-cohort 2-year BIOSOLVE-IV data. In a poster session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference 2022, principal investigator …
17
May
2022
| 09:32 Europe/Amsterdam

EuroPCR: Magmaris Resorbable Magnesium Scaffold Confirms High Safety Profile at 3 Years With BIOSOLVE-IV Data

Two poster sessions at EuroPCR focus on Magmaris’ safety profile for the first cohort after three years and the full cohort subgroup analysis at one-year follow-up

Two posters presented at the EuroPCR provided new insights into the safety profile of BIOTRONIK's Magmaris Resorbable Magnesium Scaffold (RMS). BIOSOLVE-IV study investigator Prof. Dr. Jan Torzewski, …
08
November
2021
| 09:09 Europe/Amsterdam

Superiority of BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) in Scaffold Thrombosis shown versus Abbott’s Absorb Bioresorbable Vascular Scaffold in Largest Patient Cohort to Date

BIOSOLVE-IV Registry one-year follow up data, analyzing 2,066 patients showed Superiority of BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) versus Abbott’s Absorb Bioresorbable Vascular Scaffold in Scaffold Thrombosis*

Superiority of the Magmaris sirolimus-eluting bioresorbable magnesium scaffold with regard to probable or definite scaffold thrombosis compared to a historical control group of Absorb scaffold data …
18
May
2021
| 09:00 Europe/Amsterdam

Real-World Data Confirms Long-Term Safety and Efficacy of BIOTRONIK’s Bioresorbable Scaffold

BIOSOLVE-IV registry two-year data show low event rates for the Magmaris RMS, comparable to second generation drug-eluting stents

New, long-term follow-up data from the BIOSOLVE-IV real-world registry strengthens the clinical evidence for BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) as a therapy option for patients …
15
November
2020
| 17:56 Europe/Amsterdam

Future of Resorbable Scaffolds Looks Rosier

As more data comes in, there’s plenty of reasons to be optimistic about scaffolds

In their short time on the market, bioresorbable vascular scaffolds have generated plenty of discussion within interventional cardiology. According to the authors of “Fading Away or Hope for the …
30
September
2019
| 00:00 Europe/Amsterdam

TCT 2019: Real-World Registry Data Confirm Safety of Resorbable Scaffold Technology

Magmaris Scaffold Shows Low Complication Rates, Benefiting Patients with Both Stable and Unstable Coronary Artery Disease

Full cohort data from the BIOSOLVE-IV registry strengthen the clinical evidence for BIOTRONIK’s Magmaris Resorbable Magnesium Scaffold (RMS) as a therapy option for patients with coronary artery …